QurAlis Announces Exclusive License on Novel Mechanism for Fragile X Syndrome (FXS) to Enable Development of First Potential Disease-Modifying Therapy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2025--
QurAlis Corporation ('QurAlis'), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced it has entered into an exclusive license agreement with UMass Chan Medical School ('UMass Chan') on a novel RNA-targeted mechanism confirmed to restore functional protein for Fragile X syndrome (FXS).
Fragile X syndrome is the leading inherited form of intellectual disability and the most common single genetic cause of autism. It is a genetic condition caused by a mutation of a single gene – Fragile X messenger ribonucleoprotein 1 (FMR1) – on the X chromosome. This mutation of FMR1 causes a range of developmental problems including learning disabilities, behavioral challenges, and cognitive impairment.
QurAlis' exclusive license agreement is a result of its 2024 partnership and collaboration with UMass Chan to explore the biology of FXS to determine and confirm relevant targets that could enable antisense oligonucleotide (ASO)-mediated correction for FXS. QurAlis leveraged its deep understanding, knowledge and expertise in developing ASOs as part of the collaboration. QurAlis confirmed the findings from the original publication of the UMass Chan researchers and is advancing FMR1 as a precision medicine target in up to 80 percent of FXS patients. The mis-spliced form of FMR1, designated as FMR1-217, is widely expressed throughout cortical brain areas affected in FXS and can be measured in blood and cerebrospinal fluid. Preliminary data suggest biomarker feasibility to detect mis-splicing of FMR1 in patients with FXS.
'FXS is a devastating neurodevelopmental disorder with no effective disease-modifying therapies available. Our initial partnership with UMass Chan confirmed that FMR1-217 is a validated genetic target for FXS,' said Kasper Roet, Ph.D., chief executive officer and co-founder of QurAlis. 'This groundbreaking discovery of a novel RNA-targeted mechanism to restore functional protein for FXS and the feasibility of a biomarker to detect mis-splicing of FMR1 in FXS patients opens up a completely new type of therapeutic approach through splice correction. We look forward to applying QurAlis' FlexASO® platform and deep knowledge and expertise of ASO splicing targets toward having a candidate nominated for IND-enabling studies in the near future, so that we can bring a potential new precision medicine option to patients.'
Joel Richter, Ph.D., the Arthur F. Koskinas Chair in Neuroscience and professor of molecular medicine at UMass Chan, and colleagues Sneha Shah, Ph.D., and Jonathan K. Watts, Ph.D., together with Elizabeth Berry-Kravis, M.D., Ph.D., at Rush University Medical Center, have shown that aberrant alternative splicing, or mis-splicing, of messenger RNA (mRNA) plays a fundamental role in FXS. In a seminal publication by the group, it was revealed that in FXS patients, FMR1 mRNA is still being expressed, but is mis-spliced, comprising a short, truncated alternative mRNA variant called FMR1-217 which results in non-functional FMRP protein expression. Working with patient-derived cells, Dr. Richter's lab and Dr. Berry-Kravis initially demonstrated that ASOs can successfully inhibit the mis-splicing, reduce expression of FMR1-217, rescue proper FMR1 mRNA, and restore FMRP protein expression.
'This is a meaningful step in the process of taking basic biological discoveries and turning them into practical therapies that can benefit patients in the clinic,' said Dr. Richter. 'QurAlis' platform and expertise in neurodegenerative disorders are industry leading and well positioned to address the mis-splicing of FMR1 RNA and restore functional FMRP protein expression. This partnership has not only validated our years-long research but also has resulted in the confirmation of a novel target for FXS, which we hope will lead to much-needed treatment options for FXS patients and their families.'
Dr. Berry-Kravis added, 'I am very excited that we will be able to continue development of this potential genetically based disease-modifying FMRP-restoring therapy that is expected to have a major impact on the FXS field and the spectrum of treatment options available to improve function in people with FXS.'
An orphan disease, FXS affects approximately 87,000 individuals in the U.S. alone – one in 4,000 men and one in 6,000 women. Though FXS occurs in both genders, males are more frequently affected than females, and generally with greater severity. In addition to intellectual disability, FXS patients endure a wide range of disabling symptoms including severe anxiety, social aversion, hyperactivity and attention deficit, sensory hypersensitivity, aggression, developmental seizures, and others. There are no effective disease-modifying therapies currently available for FXS.
ASOs are short, engineered single-stranded DNA/RNA molecules that can selectively bind RNA to regulate its expression in the cell. ASO technology has been leading in the field of protein regulation and has since allowed us to develop treatments for neurodegenerative disease by changing the expression of genes connected to the disease.
QurAlis' FlexASO® platform was developed to generate splice-switching ASOs with improved potency, increased therapeutic index and improved bio-distribution. This bespoke platform has the potential to tackle the spectrum of neurodegenerative and neurological diseases.
About QurAlis Corporation
At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250515683206/en/
CONTACT: Kathy Vincent
[email protected]
310-403-8951
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: RESEARCH NEUROLOGY GENETICS BIOTECHNOLOGY HEALTH UNIVERSITY PHARMACEUTICAL SCIENCE EDUCATION
SOURCE: QurAlis Corporation
Copyright Business Wire 2025.
PUB: 05/15/2025 07:45 AM/DISC: 05/15/2025 07:44 AM
http://www.businesswire.com/news/home/20250515683206/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
12 hours ago
- New York Post
Online shopper slammed with a $1K tariff bill after ordering from popular retailer: ‘I had no idea'
One woman's online shopping spree turned into a fashion fiasco — with a hefty price tag. Amanda Ivanelli, a Florida-based family vlogger, was floored when she opened her mail and found a $1,243 FedEx bill associated with a recent ASOS order. She originally ordered 'a bunch of dresses' from the British fast fashion side but only kept one or two of them, totaling about $150. Advertisement 'I got my mail today, and I got this,' she said in a now-viral TikTok, waving the invoice. 'And I open it, and I'm like, 'It's an invoice for $1,243.'' Ivanelli suspects the surprise fee was due to import tariffs — government-imposed taxes on foreign goods that President Donald Trump imposed under a rarely used 1977 emergency law. Advertisement 'I would have never ordered from ASOS or anywhere that I know I would be charged for — I'm assuming — the tariffs,' she fumed in the clip. 'Isn't that something that should have been shown at checkout?' 'I had no idea when I checked out, I had no idea,' she went on. The Post reached out to Ivanelli for comment and more details on her experience. Advertisement Fashionistas are feeling the tariff squeeze more than ever these days. The measures targeted China, Mexico, Canada and nearly every U.S. trading partner. While a federal court blocked the tariffs in May, the Trump team is expected to appeal — and shoppers are left hanging in legal limbo. It's become like a curse word, one style-savvy New Yorker dished to The Post. Advertisement Tiffany Radulescu, a 34-year-old Brooklyn glam girl, told The Post she skips the shipping stress by jet-setting to Europe for her wardrobe hauls. One Florida mom and TikTokker was recently left gasping after finding a $1.2K FedEx bill for an ASOS haul — despite only keeping a couple of dresses and returning the rest. SOPA Images/LightRocket via Getty Images 'I'd rather catch a flight than catch a tariff,' Radulescu quipped, revealing she regularly flies to Paris to scoop Prada, Hermès and Louboutin without worrying about getting dinged by Uncle Sam. And she's not the only one scheming to skirt the fees. Social media has become a runway of rage, with users bashing jaw-dropping duties that sometimes exceed the cost of the clothes themselves. Big brands like Walmart, Nike and Macy's have hiked domestic prices to cover the added costs, while luxury houses like Louis Vuitton and Hermès have padded US prices to keep profits intact. Even activewear giant Lululemon has been feeling it. Advertisement 'We are not immune to macroeconomic factors such as tariffs,' chief financial officer Meghan Frank said during a recent earnings call. CEO Calvin McDonald added that while Lululemon had seen some tariff relief, the brand remains 'vigilant.' Turns out Ivanelli isn't the only fashionista shopping for clothes and getting hemmed in by hidden fees.
Yahoo
5 days ago
- Yahoo
Asos and Checkout.com partner to boost online shopping experience
UK-based online fashion retailer Asos has collaborated with global digital payments provider to enhance the online shopping experience for its customers. The collaboration aims to increase payment acceptance rates, reduce failed payments and ensure a checkout experience that aligns with Asos' speed and simplicity needs. Asos payments head Andrew Proctor stated: ' is ideally set up to meet an enterprise merchant's needs for flexibility, while still delivering seamless payments. Our customers are global and always on, [and] every interaction needs to feel effortless, from discovery to delivery. Payments are a critical part of that experience.' Asos operates on a global scale, catering to a dynamic customer base with a high volume of daily transactions. Two-thirds of Gen Z shoppers rarely visit physical stores, so the demand for seamless digital experiences is at an all-time high. The partnership with is expected to address these demands by refining the payment process. This move is expected to benefit Asos by bolstering customer satisfaction and loyalty in its key markets. chief revenue officer Antoine Nougué stated: 'Asos is one of the most recognisable and forward-thinking brands in global fashion. 'They understand exactly how to engage a digital-first audience and set the pace for what modern e-commerce should look like. As a digital payments provider, is proud to support that vision by delivering the payment performance required to match their global reach and creative ambition. Our platform ensures that the payment experience doesn't slow down the moment, helping Asos stay ahead of the expectations of a fast-moving digital generation.' In May 2025, Asos collaborated with InPost, a provider of automated parcel machine services, to introduce nationwide next-day delivery service to lockers. "Asos and partner to boost online shopping experience" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Forbes
6 days ago
- Forbes
Bosses Pledge To Topshop Store As U.K. Fashion Icon Plots Return
After four years away, a Topshop store could be back on main street by August as the famous U.K. fashion retailer plans a return to bricks and mortar. The once hugely successful fashion brand, which was founded in 1964, had more than 500 stores across the world at the peak of its fame and was one of the most prominent names on the British high street. Topshop was one of the powerhouses of the global apparel world in the late 1990s and early 2000s and was the flagship of Sir Philip Green's all-encompassing Arcadia empire, with stores worldwide including on Fifth Avenue, New York. The company's global flagship on the junction of Regent Street and Oxford Street in the heart of London's West End was a huge draw for shoppers of all ages and Topshop became the queen of cheap chic. Its iconic flagship was recently reopened as an urban IKEA store by the Swedish giant. However, since its stores closed in 2021, the retailer has focused on selling its apparel via the likes of online retailer Asos and through pop-ups. In September last year, Asos sold a 75% stake in Topshop and Topman to the Heartland, an arm of Bestseller. Asos sold the majority stake in the business for $178 million to the Danish fashion business controlled by the major Asos shareholder Anders Povlsen, who already owns popular European retail brands including Jack & Jones and Vero Moda via his Bestseller business. The deal helped it repay debts and at the time there were rumors that the deal could see the brand return to the high stree. Asos acquired Topshop with other brands just over three years prior for nearly $435 million. Last month, Topshop hosted a pop-up event at Defected Records in East London, which drew in huge crowds and bosses have now said that the overwhelming reaction from the public has led to discussions about the brand's future. Speaking to Drapers about future plans for physical stores, Topshop managing director Michelle Wilson said that it was something that the company had been working on 'all the time' and confirmed that the retailer will have a permanent store presence 'at some point'. Wilson said: 'In the shorter term that will be something with partner support and in the longer term we will do something standalone.' She added that the return of Topshop will begin through working with wholesale partnerships from this August, before relaunching standalone stores. Much of the excitement surrounding the relaunch has been shaped by the brand's own social media. 'We promised on socials that we would be there in August,' said Wilson. 'We have something planned in August to bring Topshop back into real life again, with a more semi-permanent presence than the one-day pop-up.' Wilson was appointed managing director of the apparel brands Topshop and Topman in February, along with Moses Rashid, founder of sneaker resale site The Edit Ldn, who became global marketing director. First part of Sir Philip Green's Arcadia Group, the Topshop and Topman brands were snapped up in 2021 by Asos, alongside Miss Selfridge, after Topshop fell into administration in late 2020 as part of the collapse of Green's retail group as the disgraced former retail guru saw his business empire fall apart. Asos retained a 22.5% stake and its Topshop partner, the Seattle-based department store group Nordstrom, which owns just over 2% of the business, with Heartland controlling the remainder. Heartland is an investment and holding company representing the interests of the Holch Povlsen family, and their family business Bestseller, and it completed the deal through its subsidiary Aktieslskabet, pledging to look at the viability of a Topshop store.
